NAD on extrapolated science
This article was originally published in The Tan Sheet
Age-Less Rx marketer Medical Research Institute provided "no scientific data directly involving its product as specifically formulated for sale," according to the National Advertising Division of the Council of Better Business Bureaus. The watchdog group acknowledges a company may substantiate health performance claims without clinical studies of the specific product, but "an advertiser must demonstrate by reliable evidence that it is scientifically sound to extrapolate the conclusions drawn from other studies and data" and use them for the performance claimed for the product, NAD states in Sept. 12 release. NAD recommends the firm discontinue claims such as, "rejuvenates your body's cells to give you glowing, radiant skin and increased energy." The division also recommend Nutrition 21 modify its performance claims due to the limited "real world" applicability of the data (see story p. 10)...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.